Physician's Main :: Safety :: Other Safety Information

A powerful balance between efficacy and safety

Well tolerated with no known drug interactions#1

  • Bypasses GI tract
    • Absorption through the nasal mucosa means active drug directly enters the bloodstream1
    • Minimal GI events and no esophageal adverse events1
    • Can be administered any time of the day, without concern for eating and drinking1
  • No treatment-emergent leg cramps or venous thromboembolic events1
  • Limited systemic adverse events1

    •  

HOME | PRESCRIBING INFORMATION | CORPORATE | PRIVACY POLICY | LEGAL NOTICES


IMPORTANT SAFETY INFORMATION
Indicated for the treatment of postmenopausal osteoporosis in women greater than 5 years postmenopause with low bone mass relative to healthy premenopausal women. Recommended in conjunction with adequate calcium and vitamin D intake. The most common adverse events were rhinitis, other nasal symptoms, back pain, arthralgia, epistaxis, and headache. Periodic nasal examinations are recommended; if nasal ulceration occurs, discontinue treatment until healed. Because calcitonin-salmon is a protein, the possibility of systemic allergic reaction exists. Please refer to full prescribing information.